Adalimumab News and Research

RSS

Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.

Engineered CAR-T cells offer potential rheumatoid arthritis cure

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a reality that new research from Tsinghua University may soon begin to change.

22 Jun 2026

AGA issues updated guidance for pharmacologic treatment of moderate-to-severe Crohn's disease

The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the pharmacological management of moderate-to-severe Crohn's disease.

20 Nov 2025

Understanding immune drift in biologic therapy for inflammatory skin diseases

Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4).

28 Jul 2025

AI predicts effective treatment for rare disease using existing medications

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

5 Feb 2025

Anti-TNF drugs proven to prevent perianal fistulas in Crohn's Disease

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's disease.

23 Dec 2024

Study: Early advanced therapy significantly improves Crohn's disease outcomes

A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve outcomes, including by reducing the number of people requiring urgent abdominal surgery for treatment of their disease by ten-fold.

22 Feb 2024

A new test could save arthritis patients time, money, and pain. But will it be used?

Erinn Maury knew Remicade wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful joints hadn't responded to Enbrel or Humira, two drugs in the same class.

20 Dec 2023

Charting the future of IBD treatment: From immune modulators to microRNA therapies

In a recent study published in the journal eGastroenterology, researchers delved into the latest therapeutic strategies for managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The paper discusses emerging treatments ranging from immune-modulating drugs and biologics to novel approaches like microRNA upregulators and stem cell therapies, highlighting the need for precision medicine in IBD care.

8 Nov 2023

Using TNF inhibitors during pregnancy not associated with worse fetal or obstetric outcomes

According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477).

7 Nov 2023

Novel and emerging therapies offer new hope for patients with inflammatory bowel disease

Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) that affect the gastrointestinal tract.

7 Nov 2023

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

Like several immunosuppressive biologics, the JAK inhibitor upadacitinib is also approved for the treatment of Crohn's disease. Commissioned by the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated in an early benefit assessment whether the drug offers an added benefit versus the appropriate comparator therapy to patients with moderate to severe active Crohn's disease who have had an inadequate response, lost response or are intolerant to conventional therapy or a biologic agent.

25 Oct 2023

Beyond the gut: Crohn's disease's oral clues for timely diagnosis

The oral manifestations of CD.

12 Oct 2023

Effectiveness of Lactobacillus in treating inflammatory bowel disease

The role of Lactobacillus in treating inflammatory bowel disease.

4 Oct 2023

How have inflammatory bowel disease treatments changed after the introduction of biologics?

Researchers compared changes in inflammatory bowel disease treatment strategies before and after the introduction of biologics in Japan.

24 Aug 2023

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

"Smart" sutures can detect inflammation and release drugs

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

16 May 2023

Clinical trial findings may be a game changer in the treatment of pediatric Crohn's disease

Crohn's disease is a lifelong inflammatory bowel disease (IBD) that is characterized by swelling in the lining of the digestive tract, causing severe diarrhea, abdominal pain, and rectal bleeding.

3 Apr 2023

Study suggests mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19

Researchers investigated whether mRNA technology-based COVID-19 vaccines promote the development of autoantibodies.

14 Mar 2023

Study shows how arthritis affects people's working lives

The typical person living with arthritis in the UK is 20% less likely to be in work than their equivalent without the condition, new research shows.

30 Jan 2023

New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

The American Society of Colon and Rectal Surgeons has issued updated guidelines for physicians, published in Diseases of the Colon & Rectum, about how to treat problems of the anus and rectum called anorectal abscess, anal fistula, and rectovaginal fistula.

22 Jul 2022